Navigation Links
A Statement from Nova Oculus Concerning Clinical Trials for AMD in Canada
Date:3/14/2019

ON NOVEMBER 27, 2018, Nova Oculus Partners, LLC, issued a press release announcing that its Canadian partner, the Eye Machine Canada Inc., had been given approval to begin a clinical patient trial in Edmonton, Canada, using Nova Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD).

The previous month, the medical devices bureau of Health Canada had granted an Investigational Testing Authorization for that trial. In making that announcement, the press release also reported that approval of the trial’s protocol and its investigator has been given by the clinical trials committee of the Health Research Ethics Board of Alberta (HREBA).

However, the press release’s assertion that approval of the protocol and the study’s investigator by the clinical trials committee was in error. It was the result of a misunderstanding based on a communication from HREBA that was assumed to be granting such approval. As of today’s date, the Eye Machine Canada Inc. is still awaiting the committee’s approval to proceed with the study.

Nova Oculus Partners, LLC, did not intend to suggest there was approval that at the time it did not believe had actually been granted. Moreover, upon learning of the actual status of the application, Nova Oculus made it clear in subsequent direct communications with its investors that the Eye Machine Canada is still awaiting approval from HREBA of its protocol.

Nova Oculus Partners, LLC, unreservedly apologizes to the members of HREBA, to its clinical trials committee, to the Eye Machine Canada Inc., and to the trial’s investigators for this misunderstanding.

Read the full story at https://www.prweb.com/releases/a_statement_from_nova_oculus_concerning_clinical_trials_for_amd_in_canada/prweb16165557.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Biohaven Files Registration Statement for Proposed Public Offering of its Common Shares
2. BioAmber Issues Statement Required by Section 610(b) of the NYSE MKT Company Guide
3. ASBMT Official Statement Opposing Executive Order on Immigration
4. ASBM Statement on Final Guidance for Industry Nonproprietary Naming of Biological Products
5. Neurotrope Issues Statement On Eli Lillys Solanezumab
6. BIOREM Responds to Statement of Claim
7. Intrexon Expresses Support for Resident Commissioner of Puerto Ricos Statements on Combatting Aedes aegypti Mosquitoes in Puerto Rico and Other U.S. Jurisdictions
8. Lone Star Value Issues Statement To Fellow Enzo Shareholders
9. NW Bio Statement Regarding Appointments
10. NW Bio Issues Statement on Highly Unusual Trading Activity
11. Depomed Issues Statement on Horizon Pharma plcs Unsolicited Exchange Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/12/2019)... LITTLETON, Colo. (PRWEB) , ... March 11, 2019 ... ... now the first hospital system in Colorado, and among the first in the ... satisfaction scores around lab draws, IV placement and overall degree to which staff ...
(Date:3/11/2019)... ... 2019 , ... USDM Life Sciences and Generis have ... in GxP compliance for the life sciences industry. USDM Cloud Assurance delivers ... compliance for Generis’ flagship product, CARA. , Presentation One:, What: ...
(Date:3/5/2019)... ... 05, 2019 , ... San Fransisko, or Sisko for short, is a German ... old to pursue a career in dressage. According to Deborah, dressage came easy ... she’d ever worked with. Unfortunately, Sisko suffered an injury while playing in his ...
(Date:2/27/2019)... ... 27, 2019 , ... Lajollacooks4u is pleased to announce that ... and cooking events company will be offering a new cooking package available to ... team-building event involves pairing two popular items together – tacos and tequila – ...
Breaking Biology Technology:
(Date:3/19/2019)... SEATTLE (PRWEB) , ... March 19, 2019 , ... ... name to EMulate Therapeutics, Inc. The name change is effective immediately ... cancers and other serious diseases. , In making the announcement, Chris Rivera, ...
(Date:3/18/2019)... ... March 18, 2019 , ... Early engagement not ... patient perspective and improves participation by better balancing scientific objectives with patient goals. ... patient in the entire process from development to market. Involving these groups in ...
(Date:3/13/2019)... MOUNTAIN VIEW, Calif. (PRWEB) , ... March 13, 2019 , ... ... for up to 45 percent of the world’s population. One billion ... person's breathing is interrupted during sleep - more than 80 percent of whom go ...
Breaking Biology News(10 mins):